HANXBIO-B (03378.HK): Ties Up with Ditu Zhiyuan on BioAI Platform
NewTimeSpace News: On 16 November 2026, Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (stock code: 03378) announced that it formally entered into a research cooperation agreement with Suzhou Ditu Zhiyuan Biotechnology Co., Ltd. on 11 November 2026.
The two parties will use the Meritudio BioAI cloud platform independently developed by Ditu Zhiyuan to conduct translational and clinical medical research on Hanx Biopharmaceuticals' proprietary innovative oncology pipeline. By combining artificial intelligence, multi-omics bioinformatics and clinical big data analysis, the collaboration will provide big data support and AI guidance for preclinical and translational research plans and clinical development strategies.
Ditu Zhiyuan, based in the Suzhou Industrial Park, provides R&D services and software to the biopharma industry; its Meritudio BioAI platform consolidates data scattered across experiments, clinical work and literature into a basis for project evaluation, mechanism-of-action studies and clinical development decisions. Hanx Biopharmaceuticals, founded in 2014, focuses on structural biology, translational medicine and clinical development for next-generation immunotherapies. The announcement carries the Rule 18A.05 warning that the relevant products may not ultimately be successfully developed and marketed.
- HANXBIO-B (3378.HK): Signs Strategic Cooperation and XtalPi Science Platform Licensing Deals With XtalPi
- HANXBIO-B(03378.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 36.88 million, loss widened by 1.22% YoY
- HANXBIO-B(03378.HK): Signs AI Drug R&D Cooperation Agreement with Frontier Interdisciplinary Research Center of Huazhong University of Science and Technology
- HANXBIO-B(03378.HK) Included in FTSE Global Micro Cap Index
- HANXBIO-B(03378.HK): Research Results of Four Innovative Drugs to Be Presented at AACR 2026